- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Chugai Q1 2026: Starkes Auslandsgeschäft und Pipeline-Fortschritte treiben Wachstum an | 10 | Investing.com Deutsch | ||
| 24.04. | Chugai Q1 2026 slides: overseas sales surge, pipeline advances | 18 | Investing.com | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 24.04. | Chugai Pharmaceutical meldet starkes Umsatzwachstum für Q1 2026, Aktie gibt dennoch nach | 11 | Investing.com Deutsch | ||
| 24.04. | Chugai Pharmaceutical reports Q1 results | 2 | Seeking Alpha | ||
| 24.04. | Chugai Pharma Q1 Results Climb, Backs FY26 Outlook | 499 | AFX News | TOKYO (dpa-AFX) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlookIn the first... ► Artikel lesen | |
| 20.04. | Chugai Pharmaceutical: Starke Verkaufsstarts bei Adipositas-Medikament treiben Aktie an | 2 | Investing.com Deutsch | ||
| 20.04. | Chugai Pharmaceutical Ends Trading Day Up 5.9% on Favorable Obesity Drug Data | 3 | AASTOCKS | ||
| 13.03. | Excillum and Chugai Technos announce partnership to introduce advanced battery inspection systems in Japan | 5 | Cision News | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 6 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 10 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 494 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 570 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 536 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 601 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 552 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 17.10.25 | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 701 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| 19.06.25 | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | 855 | JCN Newswire | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 6,970 | +0,58 % | Trulieve Cannabis Corp.: Trulieve Reports Profitable First Quarter 2026 Results Bolstered by Margins and Cash Flow Generation | First quarter revenue of $287 million, with 59% gross margin
Positive net income of $2 million and Adjusted EBITDA of $100 million*
Rescheduling of medical... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 265,90 | +0,04 % | Investors Await Damage Assessment After West Pharmaceutical Cyberattack | ||
| SHIONOGI | 15,290 | +0,69 % | Shionogi & Co., Ltd. Profit Climbs In Full Year | TOKYO (dpa-AFX) - Shionogi & Co., Ltd. (SGIOF) revealed earnings for its full year that Increased, from last yearThe company's bottom line totaled JPY205.159 billion, or JPY241.04 per share.... ► Artikel lesen | |
| KALA BIO | 0,067 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 11.05.2026 | Das Instrument ARRD LU1598757687 ARCELORMITTAL S.A. NOUV. EQUITY wird cum Kapitalmassnahme gehandelt am 11.05.2026 und ex Kapitalmassnahme am 12.05.2026 The instrument ARRD LU1598757687 ARCELORMITTAL... ► Artikel lesen | |
| CHARLOTTES WEB | 0,400 | +4,71 % | MMJ International Holdings: EU Regulators Say Charlotte's Web Hemp CBD Safety "Cannot Be Established" - So Why Is It Entering Medicare? | "As a Federal Lawsuit Challenges the CMS Cannabinoid Program, Questions Mount Over Safety Standards, Scientific Validation, and Patient Protections" stated Duane Boise CEO MMJ International Holdings.... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,414 | 0,00 % | Beximco Pharma: Gerichtsanhörung auf nach April verschoben | ||
| MIRUM PHARMACEUTICALS | 88,46 | -2,81 % | Mirum Pharmaceuticals prices $600M senior notes | ||
| LUYE PHARMA | 0,262 | -2,24 % | LUYE PHARMA (02186): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | ||
| PERCHERON THERAPEUTICS | 0,003 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.03.2026 | Das Instrument 5RR CA7502321002 RADIAL RESEARCH CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 18.03.2026 und ex Kapitalmassnahme am 19.03.2026 The instrument 5RR CA7502321002 RADIAL RESEARCH CORP.... ► Artikel lesen | |
| AYURCANN | 0,001 | 0,00 % | CSE Bulletin: Suspensions - Planet Green Metals Inc., Ayurcann Holdings Corp. | Le 9 mars/March 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| KALBE FARMA | 0,044 | 0,00 % | KLBF profit rises 13% in 2025, prepares IDR 500 billion buyback: Strong export lifts KLBF's net profit 13% to ... | ||
| AVANT BRANDS | 0,360 | 0,00 % | Avant Brands Inc.: Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders | KELOWNA, BC / ACCESS Newswire / May 4, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the voting results from its annual general and special... ► Artikel lesen | |
| EVEREST MEDICINES | 3,480 | 0,00 % | Everest Medicines Limited: Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026 | - Demonstrating a Favorable Safety Profile, Robust Immunogenicity, and Promising Preliminary EfficacyHONG KONG, Apr 22, 2026 - (ACN Newswire) - Apr 20, Everest Medicines announced that the first-in-human... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 30,600 | 0,00 % | Kobayashi Pharmaceutical Co., Ltd. Reveals Retreat In Q1 Bottom Line | ||
| MERCK KGAA | 121,30 | +7,35 % | Merck erhöht Prognose nach solidem Jahresauftakt | DJ Merck erhöht Prognose nach solidem Jahresauftakt
DOW JONES--Der Pharma- und Technologiekonzern Merck hat seine Jahresprognose nach einem soliden ersten Quartal angehoben. Der Umsatz und das... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 20,000 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.